Roberto José Pessoa de Magalhães FilhoEdvan de Queiroz CrusoéWillen BujanEloísa RivaGuilhermo Ruiz ArguellesJuan Ramon Navarro CabreraDiana Katerine GarciaGuilhermo e Quintero VegaGuilhermo ConteJosé Antonio Rosendo Macías2026-03-222026-03-22201710.1016/j.clml.2017.03.026https://doi.org/10.1016/j.clml.2017.03.026https://andeanlibrary.org/handle/123456789/51372Citaciones: 3enPomalidomideCarfilzomibMultiple myelomaBortezomibThalidomideMedicineLenalidomideLatin AmericansFamily medicineBusinessAnalysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countriesarticle